George Tziras
Directeur Général chez SMALL PHARMA INC.
Fortune : 447 982 $ au 30/04/2024
Profil
George Tziras is currently the Chief Executive Officer & Director at Small Pharma, Inc. He is also a Non-Executive Director at Small Pharma Ltd.
and the Director & Chief Business Officer at Cybin, Inc. Previously, he worked as the Chief Business Officer & Director at Unilock Capital Corp.
Mr. Tziras completed his undergraduate degree at the University of Oxford and his graduate degree at The Paul H.
Nitze School of Advanced International Studies.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CYBIN, INC.
0,17% | 05/04/2024 | 1 294 747 ( 0,17% ) | 447 982 $ | 30/04/2024 |
Postes actifs de George Tziras
| Sociétés | Poste | Début |
|---|---|---|
| SMALL PHARMA INC. | Directeur Général | 20/07/2022 |
| CYBIN INC. | Directeur/Membre du Conseil | 23/10/2023 |
Small Pharma Ltd.
 Small Pharma Ltd. Pharmaceuticals: MajorHealth Technology Small Pharma Ltd. operates as a pharmaceutical company that develops a rapid-acting antidepressant to treat patients with depression. The company was founded by Peter Rands in 2015 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 01/01/2015 |
Anciens postes connus de George Tziras
| Sociétés | Poste | Fin |
|---|---|---|
| SMALL PHARMA INC. | Directeur/Membre du Conseil | - |
Formation de George Tziras
| University of Oxford | Undergraduate Degree |
| The Paul H. Nitze School of Advanced International Studies | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SMALL PHARMA INC. | Retail Trade |
| CYBIN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Small Pharma Ltd.
Small Pharma Ltd. Pharmaceuticals: MajorHealth Technology Small Pharma Ltd. operates as a pharmaceutical company that develops a rapid-acting antidepressant to treat patients with depression. The company was founded by Peter Rands in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Unilock Capital Corp.
 Unilock Capital Corp. Financial ConglomeratesFinance Unilock Capital Corp. is a development stage company, which engages in the identification and evaluation of assets or businesses with a view to completing a qualifying transaction. It intends to become a capital pool industry. The company was founded on January 23, 2018 and is headquartered in Vancouver, Canada. | Finance |
